{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:57Z","timestamp":1790821557713,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40263-026-01328-2","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T17:50:29Z","timestamp":1786557029000},"page":"1357-1367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Heterogeneity in Teriflunomide Treatment Arms: A Systematic Review and Meta\u2011Regression of Randomised Multiple Sclerosis Trials"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3823-4000","authenticated-orcid":false,"given":"Francesca","family":"Bovis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6289-9144","authenticated-orcid":false,"given":"Alessio","family":"Signori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0777-6106","authenticated-orcid":false,"given":"Mirko","family":"Capanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0302-393X","authenticated-orcid":false,"given":"Noemi","family":"Montobbio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-104X","authenticated-orcid":false,"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"5","key":"1328_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","volume":"78","author":"L Kappos","year":"2021","unstructured":"Kappos L, Fox RJ, Burcklen M, Freedman MS, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomised clinical trial. JAMA Neurol. 2021;78(5):558\u201367. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0405.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1328_CR2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1917246.","journal-title":"N Engl J Med"},{"issue":"8","key":"1328_CR3","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman L, Fox E, Hartung HP, et al. Ublituximab versus Teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2201904.","journal-title":"N Engl J Med"},{"issue":"11","key":"1328_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","volume":"23","author":"X Montalban","year":"2024","unstructured":"Montalban X, Vermersch P, Arnold DL, et al. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, Phase 3 trials. Lancet Neurol. 2024;23(11):1119\u201332. https:\/\/doi.org\/10.1016\/S1474-4422(24)00328-4.","journal-title":"Lancet Neurol"},{"issue":"19","key":"1328_CR5","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa2415985","volume":"392","author":"J Oh","year":"2025","unstructured":"Oh J, Arnold DL, Cree BAC, et al. Tolebrutinib versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2025;392(19):1893\u2013904. https:\/\/doi.org\/10.1056\/NEJMoa2415985.","journal-title":"N Engl J Med"},{"issue":"12","key":"1328_CR6","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1177\/1352458510379246","volume":"16","author":"S Inusah","year":"2010","unstructured":"Inusah S, Sormani MP, Cofield SS, et al. Assessing changes in relapse rates in multiple sclerosis. Mult Scler. 2010;16(12):1414\u201321. https:\/\/doi.org\/10.1177\/1352458510379246.","journal-title":"Mult Scler"},{"issue":"10","key":"1328_CR7","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1177\/1352458511406309","volume":"17","author":"R Nicholas","year":"2011","unstructured":"Nicholas R, Straube S, Schmidli H, et al. Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design. Mult Scler. 2011;17(10):1211\u20137. https:\/\/doi.org\/10.1177\/1352458511406309.","journal-title":"Mult Scler"},{"issue":"9","key":"1328_CR8","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1177\/1352458511435715","volume":"18","author":"R Nicholas","year":"2012","unstructured":"Nicholas R, Straube S, Schmidli H, et al. Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis. Mult Scler. 2012;18(9):1290\u20136. https:\/\/doi.org\/10.1177\/1352458511435715.","journal-title":"Mult Scler"},{"issue":"9","key":"1328_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137052","volume":"10","author":"C R\u00f6ver","year":"2015","unstructured":"R\u00f6ver C, Nicholas R, Straube S, et al. Changing EDSS progression in placebo cohorts in relapsing MS: a systematic review and meta-regression. PLoS ONE. 2015;10(9):e0137052. https:\/\/doi.org\/10.1371\/journal.pone.0137052.","journal-title":"PLoS ONE"},{"issue":"11","key":"1328_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050347","volume":"7","author":"JP Stellmann","year":"1990","unstructured":"Stellmann JP, Neuhaus A, Herich L, et al. Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data. PLoS ONE. 1990;7(11):e50347. https:\/\/doi.org\/10.1371\/journal.pone.0050347.","journal-title":"PLoS ONE"},{"issue":"12","key":"1328_CR11","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1177\/1352458513481009","volume":"19","author":"SM Steinvorth","year":"2013","unstructured":"Steinvorth SM, R\u00f6ver C, Schneider S, et al. Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression. Mult Scler. 2013;19(12):1580\u20136. https:\/\/doi.org\/10.1177\/1352458513481009.","journal-title":"Mult Scler"},{"key":"1328_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"14","key":"1328_CR13","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O'Connor","year":"2011","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293\u2013303. https:\/\/doi.org\/10.1056\/NEJMoa1014656.","journal-title":"N Engl J Med"},{"issue":"3","key":"1328_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","volume":"13","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Neurol. 2014;13(3):247\u201356. https:\/\/doi.org\/10.1016\/S1474-4422(13)70308-9.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1328_CR15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/1352458513507821","volume":"20","author":"P Vermersch","year":"2014","unstructured":"Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled Phase 3 trial. Mult Scler. 2014;20(6):705\u201316. https:\/\/doi.org\/10.1177\/1352458513507821.","journal-title":"Mult Scler"},{"issue":"4","key":"1328_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/ana.25323","volume":"84","author":"F Bovis","year":"2018","unstructured":"Bovis F, Signori A, Carmisciano L, et al. Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas. Ann Neurol. 2018;84(4):621\u20135. https:\/\/doi.org\/10.1002\/ana.25323.","journal-title":"Ann Neurol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01328-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01328-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01328-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:59:52Z","timestamp":1789048792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01328-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1328"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01328-2","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors received no financial support for the research, authorship, and\/or publication of this article.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article:\u00a0FB, MC and NM have nothing to disclose; AS received speaker\u2019s honoraria from Chiesi, Novartis and Horizon and grant from MSBase outside from this work; MPS received consulting fees from Roche, Biogen, Merck, Novartis, Sanofi, Celgene, Immunic, Geneuro, GSK, Medday; received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events from Roche, Biogen Merck, Novartis, Sanofi, Celgene; participated on a Data Safety Monitoring Board or Advisory Board for Roche, Sanofi, Novartis, Merck. She is an Editorial Board member of\n                      CNS Drugs\n                      . She was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FB and MPS conceived and designed the study. FB and MC performed the literature search, study screening, and data extraction. FB, AS, and MPS contributed to the statistical analysis and interpretation of the results. NM and MC contributed to data verification and critical interpretation of the findings. FB drafted the manuscript. AS, MC, NM, and MPS critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript and agree to be accountable for all aspects of the work.","order":3,"name":"Ethics","label":"Authors\u2019 Contribution","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for Participation","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":8,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}